{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011868","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.599336+00:00","generated_at":"2026-05-20T22:54:03.406372+00:00","sec_items":["3.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir Pharmaceuticals raises $3M via premium equity sale from largest shareholder","bullets":["$3 million raised via direct investment by Bayshore Trust (largest shareholder) at $3.00/share, 18% premium to $2.54 close.","1 million restricted shares issued; no warrants, no discounts, no convertible features.","Proceeds to fund Telomir-1 IND submission for a rare disease indication.","Follows prior $1M investment at $7.00/share and complements $5M undrawn line of credit from same group."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011868","json":"https://secwatch.observer/filing/0001641172-25-011868.json","markdown":"https://secwatch.observer/filing/0001641172-25-011868.md","text":"https://secwatch.observer/filing/0001641172-25-011868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225011868/0001641172-25-011868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225011868/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:54:03.406372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}